JP5746015B2 - Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 - Google Patents

Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 Download PDF

Info

Publication number
JP5746015B2
JP5746015B2 JP2011504377A JP2011504377A JP5746015B2 JP 5746015 B2 JP5746015 B2 JP 5746015B2 JP 2011504377 A JP2011504377 A JP 2011504377A JP 2011504377 A JP2011504377 A JP 2011504377A JP 5746015 B2 JP5746015 B2 JP 5746015B2
Authority
JP
Japan
Prior art keywords
quinolin
yloxy
phenyl
fluoro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517689A (ja
JP2011517689A5 (cg-RX-API-DMAC7.html
Inventor
アクセル ウルリッヒ
アクセル ウルリッヒ
ピョートル クニャゼフ
ピョートル クニャゼフ
イーシャン ジャン
イーシャン ジャン
ケリー ジョルジー
ケリー ジョルジー
ラズロ オルフィ
ラズロ オルフィ
シュトヴァーン サバトカイ
シュトヴァーン サバトカイ
Original Assignee
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー, マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー filed Critical マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
Publication of JP2011517689A publication Critical patent/JP2011517689A/ja
Publication of JP2011517689A5 publication Critical patent/JP2011517689A5/ja
Application granted granted Critical
Publication of JP5746015B2 publication Critical patent/JP5746015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011504377A 2008-04-16 2009-04-16 Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 Active JP5746015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4539808P 2008-04-16 2008-04-16
US61/045,398 2008-04-16
PCT/EP2009/002798 WO2009127417A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2011517689A JP2011517689A (ja) 2011-06-16
JP2011517689A5 JP2011517689A5 (cg-RX-API-DMAC7.html) 2012-05-31
JP5746015B2 true JP5746015B2 (ja) 2015-07-08

Family

ID=40999731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504377A Active JP5746015B2 (ja) 2008-04-16 2009-04-16 Ａｘｌキナーゼ阻害剤としてのキノリン誘導体

Country Status (12)

Country Link
US (1) US9206130B2 (cg-RX-API-DMAC7.html)
EP (1) EP2262772B8 (cg-RX-API-DMAC7.html)
JP (1) JP5746015B2 (cg-RX-API-DMAC7.html)
KR (1) KR101325237B1 (cg-RX-API-DMAC7.html)
CN (1) CN102131783A (cg-RX-API-DMAC7.html)
AU (1) AU2009237938A1 (cg-RX-API-DMAC7.html)
CA (1) CA2718538A1 (cg-RX-API-DMAC7.html)
ES (1) ES2391373T3 (cg-RX-API-DMAC7.html)
IL (1) IL208103A (cg-RX-API-DMAC7.html)
MX (1) MX2010011224A (cg-RX-API-DMAC7.html)
RU (1) RU2010146474A (cg-RX-API-DMAC7.html)
WO (1) WO2009127417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
PT2780338T (pt) 2011-11-14 2017-02-17 Ignyta Inc Derivados de uracil como inibidores da quinase axl e c-met
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
CA2922542A1 (en) * 2013-11-22 2015-05-28 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
WO2018139527A1 (ja) 2017-01-26 2018-08-02 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
WO2019039525A1 (ja) 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
SG11202001664VA (en) * 2017-08-31 2020-03-30 Abbvie Inc Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
IL273579B2 (en) 2017-09-27 2025-10-01 Incyte Corp Salts of pyrrolizidine derivatives used as Tm inhibitors.
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
HRP20250676T1 (hr) 2018-06-29 2025-08-01 Incyte Corporation Formulacije inhibitora axl/mer
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
AU2021268210A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
EP1153920B1 (en) * 1999-01-22 2003-10-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US20100234371A1 (en) * 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
PL2101759T3 (pl) * 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK

Also Published As

Publication number Publication date
KR101325237B1 (ko) 2013-11-04
MX2010011224A (es) 2011-02-25
KR20100132038A (ko) 2010-12-16
JP2011517689A (ja) 2011-06-16
US9206130B2 (en) 2015-12-08
EP2262772B8 (en) 2013-03-13
RU2010146474A (ru) 2012-05-27
IL208103A0 (en) 2010-12-30
CA2718538A1 (en) 2009-10-22
US20110092503A1 (en) 2011-04-21
AU2009237938A1 (en) 2009-10-22
WO2009127417A1 (en) 2009-10-22
IL208103A (en) 2015-08-31
ES2391373T3 (es) 2012-11-23
EP2262772A1 (en) 2010-12-22
CN102131783A (zh) 2011-07-20
EP2262772B1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
JP5746015B2 (ja) Ａｘｌキナーゼ阻害剤としてのキノリン誘導体
AU2010214095B2 (en) Novel amino azaheterocyclic carboxamides
EP1415987B1 (en) Nitrogenous aromatic ring compounds as anti cancer agents
CN102977014B (zh) 新的喹啉类化合物及其用途
BR112020025869A2 (pt) compostos
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
KR20050034732A (ko) 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
CN107098846B (zh) N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
NO336275B1 (no) Forbindelse, angitt som quinazolinanalog som reseptor tyrosin kinaseinhibitor, anvendelse derav for fremstilling av et medikament, samt farmasøytisk sammensetning omfattende forbindelsen
JP2008266295A (ja) キナーセ゛阻害活性を有する新規チアシ゛アソ゛ール誘導体
CN106478606B (zh) N-取代吲哚类衍生物及其应用
CN107056755B (zh) 五元杂环酰胺类wnt通路抑制剂
US20250136580A1 (en) Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
ES2334708T3 (es) (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
CN104876878A (zh) 5-芳基酚-2烷基取代脲苯并咪唑类化合物及其应用
HK1156952A (en) Quinoline derivatives as axl kinase inhibitors
CN105263926B (zh) 苯并噻吩化合物
RU2838187C2 (ru) Соединения
TW202521522A (zh) 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物
CN117343046A (zh) 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
CN102432592A (zh) 具有抗肿瘤作用的芳基脲衍生物及其制备方法
JP2008519085A (ja) アミド誘導体、それらの製造及び医薬品としての使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150507

R150 Certificate of patent or registration of utility model

Ref document number: 5746015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250